Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

Hisun In-Licenses China Rights to Celsion’s Cancer Drug for $100 Million

publication date: Jan 22, 2013
Zhejiang Hisun Pharma has in-licensed China rights to ThermoDox®, a liver cancer drug developed by Celsion Corporation, in a deal that totals $100 million in upfront and milestone payments. Celsion is expected to announce results from a Phase III trial of the drug later this month. In May 2012, Celsion chose Hisun as its global manufacturer for ThermoDox. Celsion expects the deal to be worth “hundreds of million of dollars” over time in milestones and royalties, given the prevalence of liver cancer in China. More details....

Stock Symbols: (SHA: 600267) (NSDQ: CLSN)

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Events
The 9th China Healthcare Investment Conference
Shanghai, China
March 27-29, 2018
Use chinabio18 for 20% discount